24.07.2019 • News • Clariant • Ernesto Occhiello • Hariolf Kottmann

Clariant’s CEO Ernesto Occhiello Resigns

Ernesto Occhiello has resigned as CEO of Clariant with immediate effect....
Ernesto Occhiello has resigned as CEO of Clariant with immediate effect. Source: Clariant

Swiss chemicals major Clariant announced today that its CEO Ernesto Occhiello has resigned for personal reasons with immediate effect. Hariolf Kottmann, chairman of the company's board of directors, has assumed Occhiello's responsibilities in the interim as executive chairman.

Occhiello was appointed as CEO of Clariant in September 2018 following SABIC’s acquisition of a 24.99% stake in the Swiss company, announced in January 2018.

Clariant said that until further notice, Clariant’s Executive Committee will consist of Hariolf Kottmann, executive chairman, Patrick Jany, chief financial officer, and Hans Bohnen, chief operating officer. In order to comply with Swiss governance rules, Eveline Saupper has been appointed independent lead director of the board.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Top-Feature

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.